The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab

BACKGROUND: Immunotherapy targeting programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) has become the forefront strategy for systemic therapy in advanced non-small cell lung cancer (NSCLC) patients. PD-L1 expression on tumor cells has been reported as an eligible biomarker of respo...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Thorac Dis
Glavni autori: Matsubara, Taichi, Takamori, Shinkichi, Haratake, Naoki, Toyozawa, Ryo, Miura, Naoko, Shimokawa, Mototsugu, Yamaguchi, Masafumi, Seto, Takashi, Takenoyama, Mitsuhiro
Format: Artigo
Jezik:Inglês
Izdano: AME Publishing Company 2020
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7212122/
https://ncbi.nlm.nih.gov/pubmed/32395289
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2020.02.27
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items